Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

CareDx

COMPASS Pathways

Genius Sports

908 Devices

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 of Cathie Wood's Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $10

Adaptive is awaiting an approval from the FDA on solid-tumor therapy afami-cel. The company uses a T-cell receptor platform to engineer cancer therapies.

Why Shares of Adaptive Biotechnologies Jumped This Week

Equitrans Midstream

Plug Power

5 ‘Strong Buy' Stocks to Buy Under $10, and Cathie Wood's Ark Owns 2 of Them

CrowdStrike

Prime Medicine Inc

CrowdStrike, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. CrowdStrike opened 8% lower on Thursday despite a "beat and raise" quarterly report.

Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay's Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

Exact Sciences

GlaxoSmithKline

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

3 Personalized Medicine Stocks to Buy for Long-Time Returns

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 2023 RBC Capital Markets Global Healthcare Conference in New York, New York.

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive's TCR discovery platform The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive's TCR discovery platform

Adaptive Biotechnologies Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-founder, Chairman & Chief Executive Officer Tycho Peterson - Chief Financial Officer Nitin Sood - Chief Commercial Officer, MRD Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Derik De Bruin - Bank of America Yuko Oku - Morgan Stanley Tom Stevens - Cowen & Company Dustin Scaringe - William Blair Elizabeth Webster - Goldman Sachs Dan Leonard - Credit Suisse Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2023 Conference Call.

Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago.

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2023.

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SEATTLE, April 25, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, Nevada.

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

The consensus price target hints at a 49.9% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Adaptive Biotechnologies (ADPT)? Wall Street Analysts Think 49.94%

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual Cowen Healthcare Conference in Boston, Masssachusetts.

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Adaptive Biotechnologies (ADPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2022 Earnings Conference Call February 14, 2023 4:30 PM ET Corporate Participants Karina Calzadilla - VP, Investor Relations Tycho Peterson - Chief Financial Officer Sharon Benzeno - Chief Commercial Officer, Immune Medicine Nitin Sood - Chief Commercial Officer, MRD Chad Robins - Co-founder, Chairman and Chief Executive Officer Conference Call Participants Derik De Bruin - Bank of America David Westenberg - Piper Sandler Daniel Brennan - Cowen Julia Cheng- JPMorgan Mark Massaro - BTIG Elizabeth Webster - Goldman Sachs Andrew Brackmann - William Blair Sung Ji Nam - Scotia Bank Dan Leonard - Credit Suisse Operator Good day and thank you for standing by and welcome to the Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions].

Adaptive Biotechnologies Corporation (ADPT) Q4 2022 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue Estimates

SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 14, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

News for Adaptive Biotechnologies Stock (ADPT)